乌司奴单抗维持治疗溃疡性结肠炎两年有效且安全
UNIFI长期扩展研究评估乌司奴单抗皮下维持治疗中重度溃疡性结肠炎至第92周疗效和第96周安全性。399例静脉诱导应答者随机接受安慰剂、乌司奴单抗90mg每12周或每8周维持。两剂量组疗效维持至第92周,未见新安全信号。
要点
- 乌司奴单抗90mg每12周和每8周维持治疗至第92周均维持疗效。
- 第92周症状缓解率在每12周组和每8周组分别为64.5%和67.6%。
- 第44至96周乌司奴单抗联合组与安慰剂组不良事件率未见新安全信号。
核心结论
- 乌司奴单抗在溃疡性结肠炎患者中的疗效持续至第92周,未观察到新的安全信号。
研究设计与样本
- UNIFI长期扩展研究,评估皮下乌司奴单抗治疗中重度溃疡性结肠炎从第44周至第220周。
- 共399例对静脉乌司奴单抗诱导有应答并随机接受维持治疗的患者进入长期扩展:115例接受皮下安慰剂,141例接受乌司奴单抗90mg每12周,143例接受乌司奴单抗90mg每8周。
- 安慰剂治疗在第44周揭盲后停止。
- 每12周及揭盲后每次给药访视时收集部分Mayo评分,全程评估安全性。
主要发现
- 在所有随机维持治疗患者中,第92周症状缓解率(排便频率=0/1;直肠出血=0)在乌司奴单抗每12周组为64.5%,每8周组为67.6%。
- 在长期扩展中接受治疗的随机患者中,每12周组78.7%和每8周组83.2%在第92周达到症状缓解。
- 第92周达到症状缓解的患者中,每12周组和每8周组均>95%未使用皮质激素。
- 两乌司奴单抗组疗效均维持至第92周。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ongoing UNIFI long-term extension evaluates subcutaneous ustekinumab for moderate-to-severe ulcerative colitis (UC) from weeks 44 through 220. AIMS: To assess efficacy (through week 92) and safety (through week 96) during the long-term extension METHODS: Overall, 399 responders to intravenous ustekinumab induction and who were randomised to maintenance therapy were treated in the long-term extension (115 received subcutaneous placebo, 141 received ustekinumab 90 mg every 12 weeks [q12w], and 143 received ustekinumab 90 mg q8w). Placebo treatment was discontinued at unblinding after week 44. Partial Mayo scores were collected every 12 weeks and at each dosing visit after unblinding. Safety was evaluated throughout. RESULTS: Among all patients randomised in maintenance, symptomatic remission rates (stool frequency = 0/1; rectal bleeding = 0) at week 92 were, 64.5% and 67.6% in the ustekinumab q12w and q8w groups, respectively. Among randomised patients treated in the long-term extension, 78.7% and 83.2% of patients receiving q12w and q8w, respectively, attained symptomatic remission at week 92; >95% of patients in symptomatic remission at week 92 were corticosteroid-free. Both ustekinumab groups maintained efficacy through week 92. From weeks 44 to 96, adverse events (AEs) per hundred patient-years (PY) of follow-up for combined ustekinumab vs placebo were: 255.68 vs 267.93; serious AEs, 9.34 vs 12.69; malignancies (including non-melanoma skin cancers), 0.93 vs 1.49; and serious infections, 2.33 vs 2.99. One patient with multiple comorbidities who received one ustekinumab dose after dose adjusting from placebo experienced a fatal cardiac arrest. CONCLUSIONS: The efficacy of ustekinumab in patients with UC was sustained through 92 weeks. No new safety signals were observed (ClinicalTrials.gov number, NCT02407236).
引用
- Panaccione R, Danese S, Sandborn WJ, et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020. PMID: 33086438. doi:10.1111/apt.16119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。